Aurobindo Pharma Limited
AUROPHARMA
Rang in Aktien
#2073
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures,... Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Aktienkurs
$17.34
Marktkapitalisierung
$9.98B
Veränderung (1 Tag)
-3.08%
Veränderung (1 Jahr)
38.71%
Land
IN
Handel Aurobindo Pharma Limited (AUROPHARMA)
Kategorie
Healthcare
Gewinn für Aurobindo Pharma Limited (AUROPHARMA)
Gewinn im Jun 2026 TTM: $598.16M
Laut den aktuellen Finanzberichten von Aurobindo Pharma Limited betragen die aktuellen Gewinne des Unternehmens $598.16M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $525.28M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $317.90M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Aurobindo Pharma Limited von 2004 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $598.16M | 0.98% |
| 2025 | $592.37M | 12.77% |
| 2024 | $525.28M | 65.24% |
| 2023 | $317.90M | -28.45% |
| 2022 | $444.31M | -55.71% |
| 2021 | $1.00B | 101.91% |
| 2020 | $496.85M | 11.61% |
| 2019 | $445.18M | -10.57% |
| 2018 | $497.80M | 5.47% |
| 2017 | $471.99M | 13.94% |
| 2016 | $414.23M | 19.23% |
| 2015 | $347.42M | -3.94% |
| 2014 | $361.67M | 425.28% |
| 2013 | $68.85M | -263.95% |
| 2012 | $-42.00M | -123.75% |
| 2011 | $176.86M | 5.59% |
| 2010 | $167.49M | 1,070.92% |
| 2009 | $14.30M | -80.38% |
| 2008 | $72.91M | 53.10% |
| 2007 | $47.62M | 115.32% |
| 2006 | $22.12M | 427.99% |
| 2005 | $4.19M | -88.08% |
| 2004 | $35.14M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 195.00% |
IN
|
